Matches in Wikidata for { <http://www.wikidata.org/entity/Q94146303> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q94146303 description "article scientifique publié en 2018" @default.
- Q94146303 description "wetenschappelijk artikel" @default.
- Q94146303 description "наукова стаття" @default.
- Q94146303 name "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 name "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 type Item @default.
- Q94146303 label "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 label "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 prefLabel "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 prefLabel "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 P1433 Q94146303-4CA654A2-81E2-4739-A2C3-B7E2AC6F5ED7 @default.
- Q94146303 P1476 Q94146303-87EE1C83-7AE3-4DFB-9E85-988B49FAB7A8 @default.
- Q94146303 P2093 Q94146303-00F44DA6-09E2-4083-9657-F12B1739EBBF @default.
- Q94146303 P2093 Q94146303-76872A5E-E48D-4DB0-9AA3-8690E666C984 @default.
- Q94146303 P2093 Q94146303-797BF58A-D32D-4171-B621-62D12CF29C73 @default.
- Q94146303 P2093 Q94146303-B707D9D2-AD2B-4E5C-9DDB-A5B201322509 @default.
- Q94146303 P2093 Q94146303-CAB62664-7AF5-4893-B2FB-CF33579320FC @default.
- Q94146303 P2093 Q94146303-DFF21421-BF48-4AA0-8111-38B55FE4D688 @default.
- Q94146303 P304 Q94146303-649836DD-71C8-4DC6-8EC4-5CE131DF48BD @default.
- Q94146303 P31 Q94146303-D4A2EACB-430C-44AB-A68A-57F4D1637457 @default.
- Q94146303 P356 Q94146303-8521F6BF-C0CD-49A2-B6BD-06F34DF5EBB5 @default.
- Q94146303 P433 Q94146303-060FF58F-5254-407D-BB41-6FC3C24102F3 @default.
- Q94146303 P478 Q94146303-B972A14F-9AB0-47DB-9A59-C1407BFBF6F7 @default.
- Q94146303 P50 Q94146303-97B4DBC2-E2B0-4B9A-B2CF-728C39003E17 @default.
- Q94146303 P577 Q94146303-F0D4B027-4A9E-43D0-BC01-002BD8758D33 @default.
- Q94146303 P921 Q94146303-0985AE4C-5E76-433F-9A3D-2B081FACF6E2 @default.
- Q94146303 P921 Q94146303-1CD30DB2-74D7-4302-B935-A27ED88A83D8 @default.
- Q94146303 P921 Q94146303-A123A6BA-A1B0-462F-9798-168910220098 @default.
- Q94146303 P932 Q94146303-3A46EB12-EF2E-4BA0-81AB-E93F3E44B66F @default.
- Q94146303 P356 NOY148.044 @default.
- Q94146303 P1433 Q15724471 @default.
- Q94146303 P1476 "ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94146303 P2093 "Alireza Mohammadi" @default.
- Q94146303 P2093 "Cathy Brewer" @default.
- Q94146303 P2093 "David Peereboom" @default.
- Q94146303 P2093 "Manmeet Ahluwalia" @default.
- Q94146303 P2093 "Michael Vogelbaum" @default.
- Q94146303 P2093 "Tyler Alban" @default.
- Q94146303 P304 "vi12-vi13" @default.
- Q94146303 P31 Q13442814 @default.
- Q94146303 P356 "10.1093/NEUONC/NOY148.044" @default.
- Q94146303 P433 "Suppl 6" @default.
- Q94146303 P478 "20" @default.
- Q94146303 P50 Q88337055 @default.
- Q94146303 P577 "2018-11-05T00:00:00Z" @default.
- Q94146303 P921 Q282142 @default.
- Q94146303 P921 Q413299 @default.
- Q94146303 P921 Q420207 @default.
- Q94146303 P932 "6216163" @default.